{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:21Z","timestamp":1787166861178,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0236-z","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T08:23:23Z","timestamp":1533025403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Michael","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-446X","authenticated-orcid":false,"given":"Sandra A. N.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Elligsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Palmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome A.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"236_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42:S5\u201312.","journal-title":"Clin Infect Dis"},{"key":"236_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","volume":"42","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamics properties of vancomycin. Clin Infect Dis. 2006;42:S35\u20139.","journal-title":"Clin Infect Dis"},{"key":"236_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275\u20139.","journal-title":"Pharmacotherapy"},{"key":"236_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","volume":"19","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19:365\u201380.","journal-title":"J Infect Chemother"},{"key":"236_CR5","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","volume":"71","author":"Z Ye","year":"2016","unstructured":"Ye Z, Chen Y, Chen K, Zhang X, Du G, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J Antimicrob Chemother. 2016;71:3020\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"236_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4212\/cjhp.v65i1.1101","volume":"65","author":"M Elligsen","year":"2012","unstructured":"Elligsen M, Walker SA, Simor AE, Daneman N. Prospective audit and feedback of antimicrobial stewardship in critical care: program implementation, experience, and challenges. Can J Hosp Pharm. 2012;65:31\u20136.","journal-title":"Can J Hosp Pharm"},{"key":"236_CR7","doi-asserted-by":"crossref","unstructured":"Bellomo R, Ronco C, Kellum J, Mehta R, Palevsky P. Acute dialysis quality initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8:R204\u201312.","DOI":"10.1186\/cc2872"},{"key":"236_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"236_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1469-0691.2009.02901.x","volume":"15","author":"C Feldman","year":"2009","unstructured":"Feldman C, Alanee S, Yu VL, Richards GA, Ortgvist A, Rello J, et al. Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. Clin Microbiol Infect. 2009;15:850\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"236_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"236_CR11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481\u201390.","journal-title":"Clin Infect Dis"},{"key":"236_CR12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KM Itani","year":"2010","unstructured":"Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199:804\u201316.","journal-title":"Am J Surg"},{"key":"236_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1086\/368128","volume":"187","author":"G Sakoulas","year":"2003","unstructured":"Sakoulas G, Eliopoulos GM, Moellering RC, Novick RP, Venkataraman L, Wennersten C, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis. 2003;187:929\u201338.","journal-title":"J Infect Dis"},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jac\/dkm091","volume":"59","author":"W Rose","year":"2007","unstructured":"Rose W, Rybak M, Tsuji B, Kaatz G, Sakoulas G. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother. 2007;59:1190\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"236_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1128\/AAC.00671-06","volume":"51","author":"BT Tsuji","year":"2007","unstructured":"Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:1089\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"236_CR16","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1128\/AAC.01472-10","volume":"55","author":"S Zelenitsky","year":"2011","unstructured":"Zelenitsky S, Alkurdi N, Weber Z, Ariano R, Zhanel G. Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model. Antimicrob Agents Chemother. 2011;55:3627\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"236_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448\u201351.","journal-title":"Clin Infect Dis"},{"key":"236_CR18","first-page":"624","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan. 1996 MMWR Morb Mortal Wkly Rep. 1997;46:624\u20136.","journal-title":"1996 MMWR Morb Mortal Wkly Rep"},{"key":"236_CR19","first-page":"765","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:765\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"236_CR20","first-page":"813","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:813\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"236_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJM199902183400701","volume":"340","author":"TL Smith","year":"1999","unstructured":"Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493\u2013501.","journal-title":"N Engl J Med"},{"key":"236_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3201\/eid0706.010618","volume":"7","author":"JC Hageman","year":"2001","unstructured":"Hageman JC, Pegues DA, Jepson C, Bell RL, Guinan M, Ward KW, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis. 2001;7:1023\u20135.","journal-title":"Emerg Infect Dis"},{"key":"236_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1086\/346207","volume":"36","author":"SK Fridkin","year":"2003","unstructured":"Fridkin SK, Hageman J, McDougal LK, Jarvis WR, Perl TM, Tenover FC, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003;36:429\u201339.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0236-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:45Z","timestamp":1751760045000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0236-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Sunnybrook Health Sciences Centre (SHSC) Research Ethics Board on December 23rd, 2015 (Project Identification Number 497\u20132015), and was conducted in accordance with the Declaration of Helsinki and national and institutional standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}